Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells
- Development stage
- Unknown
- Lead developer
- Zhongshan Hospital, Fudan University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells is an investigational autologous CAR-T cell therapy developed by Shanghai Zhongshan Hospital for the treatment of relapsed or refractory hepatocellular carcinoma (HCC). This biologic therapy involves the ex vivo genetic engineering of a patient's T cells to express a chimeric antigen receptor (CAR) that specifically targets the Interleukin-1 receptor accessory protein (IL1RAP). IL1RAP is a cell surface protein that is significantly overexpressed in HCC compared to normal liver tissue, making it a viable target for directed immunotherapy. The therapy is currently being evaluated in a Phase 1 dose-escalation clinical trial (NCT06757881) to assess its safety, tolerability, and preliminary anti-tumor activity in adult patients.
- Other names
- IL1RAP-targeting Chimeric Antigen Receptor T CellsIL-1RAP-targeting Chimeric Antigen Receptor T CellsIL 1RAP-targeting Chimeric Antigen Receptor T Cellsanti-IL1RAP CAR-T cellsanti-IL-1RAP CAR-T cellsanti-IL 1RAP CAR-T cells
02
Targets
IL1RAP (Interleukin 1 receptor accessory protein)
Beyond the preview
Go deeper on Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells.